Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer
Authors:
- 1 December 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 256 (6) , 1014-1022
Abstract
Objective: This study was designed to evaluate the expression and prognostic significance of A Disintegrin and Metalloproteinase17 (ADAM17) protein in patients with gastric cancer. Background: Tumor invasion and metastasis are primary causes for treatment failure or death among cancer patients. ADAM17 is a multidomain transmembrane glycoprotein involved in the release of several ligands that were shown to promote tumor formation and progression. Elevated expression of ADAM17 was detected in a number of human cancers and was associated with poor progression and prognosis of the diseases. In gastric cancer, however, the expression and prognostic significance of ADAM17 has not been fully elucidated. Methods: The expressions of ADAM17 and extracellular matrix metalloproteinase inducer (EMMPRIN), a protein implicated in tumor invasion and metastasis, were detected using the tissue microarray technique and immunohistochemical EnVision method and compared with clinicopathological parameters of patients with gastric cancer. Results: The expressions of ADAM17 and EMMPRIN were upregulated in gastric cancer lesions compared with their expressions in adjacent non-cancerous tissues (P < 0.01). High expression of ADAM17 was detected in 35.78% (156/436) of patients with gastric cancer and positively correlated with the expression of EMMPRIN (r = 0.738, P < 0.01). ADAM17 expression was associated with a number of clinicopathological parameters including depth of invasion and TNM stage of the tumor (P < 0.05). In each TNM stage, patients with high ADAM17 expression had a longer mean survival time than those with low expression (P < 0.05). Particularly, the mean survival time of stage II gastric cancer patients with low ADAM17 expression was longer than that of stage I patients with high ADAM17 expression (P < 0.01). Multivariate survival analysis suggested that, along with other parameters, ADAM17 and EMMPRIN expression were independent prognostic factors for patients with gastric cancer. Conclusions: ADAM17 was implicated in the progression of gastric cancer. On the basis of the TNM stage, detection of ADAM17 expression will be helpful for predicting prognosis of gastric cancer.Keywords
This publication has 42 references indexed in Scilit:
- Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progressionBritish Journal of Cancer, 2010
- Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal CancerClinical Cancer Research, 2010
- ADAM-17: the enzyme that does it allCritical Reviews in Biochemistry and Molecular Biology, 2010
- Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor NetworkClinical Cancer Research, 2007
- Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stageBreast Cancer Research, 2007
- Epiregulin promotes proliferation and migration of renal proximal tubular cellsAmerican Journal of Physiology-Renal Physiology, 2007
- Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosisBritish Journal of Cancer, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer TherapyCancer Research, 2004
- ADAMs(A Disintegrin and Metalloproteinase) Messenger RNA Expression inHelicobacter pylori–Infected, Normal, and Neoplastic Gastric MucosaThe Journal of Infectious Diseases, 2002